{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027534","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.878596+00:00","generated_at":"2026-06-11T18:15:25.950333+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Revenue collapse to $0.2M, Q2 net loss $8.9M vs $2.7M a year ago","bullets":["Revenue $0.2M vs $5.0M in prior-year quarter as COVID test demand declined.","Operating loss of $12.0M increased from $4.1M on pre-commercialization investments in Co-Dx PCR Home platform.","Net loss $8.9M ($0.31 per share loss) compared to $2.7M loss ($0.08 per share) a year ago.","Cash and securities $69.1M; repurchased 0.4M shares at avg $1.51 for ~$0.6M.","Received $1.2M NIH RADx grant and over $2.3M from Gates Foundation for TB/HPV test development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027534","json":"https://secwatch.observer/filing/0001493152-23-027534.json","markdown":"https://secwatch.observer/filing/0001493152-23-027534.md","text":"https://secwatch.observer/filing/0001493152-23-027534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/0001493152-23-027534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:15:25.950333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61cd26f897d46705d321d81a2ecf51461457d742","claim":"Co-Diagnostics, Inc. reported second quarter 2023 results: revenue $0.2 million, net income Net loss of $8.9 million, EPS EPS loss of $0.31 per fully diluted share.","evidence_excerpt":"the development of molecular diagnostic tests, announced today financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Results: ● Revenue of $0.2 million, down from $5.0 million during the prior year primarily due to the anticipated decline in global demand for the Logix Smart® COVID-19 tests ● Operating expenses of $11.7","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/0001493152-23-027534-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$0.2 million"},{"label":"Net income","value":"Net loss of $8.9 million"},{"label":"EPS","value":"EPS loss of $0.31 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}